Maintenance Versus Reduction of Immunosuppression for Renal Transplant Patients Hospitalized With COVID-19 Disease

Inclusion Criteria: * Adults ≥18 years * COVID positive by RT-PCR or serology * ≥ 6 months post-transplant * use of anti-metabolite (mycophenolate or azathioprine) and calcineurin inhibitor (cyclosporin or tacrolimus) * informed consent; first admission during study period * participation within 72 hours of hospitalization Exclusion Criteria: * ICU care or need for invasive ventilation or use of pressors at screening/randomization * COVID-19 disease severity score more than 5 at screening/randomization * Known donor specific antibody * eGFR \<20ml/min/1.73m2 * hematocrit \<24% * biopsy proven and treated rejection within last 3 months * institutionalized individuals (prisoners) * pregnancy * participation in another clinical study with an investigational medicinal product within 30 days or within 5 half-lives of such, whichever is longer, prior to randomization and during the study * any other conditions, which, in the opinion of the investigator would make the subject unsuitable.